THE MODERN VIEW OF THE ADDITIONAL THERAPY, CORRECTING METABOLIC PARAMETERS IN PATIENTS WITH PULMONARY HYPERTENSION: TRIMETAZIDINE IN FOCUS

SUMMERY According to the Russian data 34% of patients with pulmonary hypertension (PH) have complaints of chest pain. Currently, the cause of this symptoms can be as coronary heart disease, compression of the coronary arteries (usually the left main coronary artery) dilated pulmonary artery, coronary insufficiency due to low cardiac output is relatively weak development of coronary collaterals in the hypertrophy RV wall or a reflex constriction of the coronary arteries due to distension of the pulmonary artery, to the reduction of blood oxygen saturation in the late stages of the disease. Myocardial ischemia and chest pain reduce the quality of life of patients, and to be predictors of adverse outcomes. Therefore, treatment of these patients should be comprehensive and include PAH -specific and additional metabolic therapy. The therapy of the last group - trimetazidine - being actively researched in various pathologies, and shows the positive side in studies: the Cochrane meta-analysis of patients with ischemic heart disease. Trimetazidine has a pronounced anti-anginal efficacy and good tolerability in combination with other treatment, which will improve the quality of life of patients. Keywords: pulmonary hypertension, myocardial ischemia, chest pain, trimetazidine, metabolic modulator.